1. Home
  2. XOMA vs NPCT Comparison

XOMA vs NPCT Comparison

Compare XOMA & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOMA
  • NPCT
  • Stock Information
  • Founded
  • XOMA 1981
  • NPCT 2020
  • Country
  • XOMA United States
  • NPCT United States
  • Employees
  • XOMA N/A
  • NPCT N/A
  • Industry
  • XOMA Biotechnology: Pharmaceutical Preparations
  • NPCT Investment Managers
  • Sector
  • XOMA Health Care
  • NPCT Finance
  • Exchange
  • XOMA Nasdaq
  • NPCT Nasdaq
  • Market Cap
  • XOMA 320.8M
  • NPCT 340.7M
  • IPO Year
  • XOMA N/A
  • NPCT N/A
  • Fundamental
  • Price
  • XOMA $28.59
  • NPCT $11.34
  • Analyst Decision
  • XOMA Strong Buy
  • NPCT
  • Analyst Count
  • XOMA 2
  • NPCT 0
  • Target Price
  • XOMA $78.50
  • NPCT N/A
  • AVG Volume (30 Days)
  • XOMA 18.9K
  • NPCT 107.1K
  • Earning Date
  • XOMA 11-05-2024
  • NPCT 01-01-0001
  • Dividend Yield
  • XOMA N/A
  • NPCT 9.82%
  • EPS Growth
  • XOMA N/A
  • NPCT N/A
  • EPS
  • XOMA N/A
  • NPCT N/A
  • Revenue
  • XOMA $15,239,000.00
  • NPCT N/A
  • Revenue This Year
  • XOMA $456.45
  • NPCT N/A
  • Revenue Next Year
  • XOMA $29.84
  • NPCT N/A
  • P/E Ratio
  • XOMA N/A
  • NPCT N/A
  • Revenue Growth
  • XOMA 277.95
  • NPCT N/A
  • 52 Week Low
  • XOMA $14.27
  • NPCT $8.58
  • 52 Week High
  • XOMA $30.50
  • NPCT $10.63
  • Technical
  • Relative Strength Index (RSI)
  • XOMA 53.55
  • NPCT 31.22
  • Support Level
  • XOMA $28.66
  • NPCT $11.46
  • Resistance Level
  • XOMA $30.50
  • NPCT $11.55
  • Average True Range (ATR)
  • XOMA 1.07
  • NPCT 0.15
  • MACD
  • XOMA 0.21
  • NPCT -0.05
  • Stochastic Oscillator
  • XOMA 55.56
  • NPCT 9.68

About XOMA XOMA Corporation

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest

Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.

Share on Social Networks: